Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis

Rheumatology

Volumn 47, Issue 6, 2008, Pages 865-867

  Mcgonagle, D ^a,b   Tan, A L ^b   Madden, J ^a   Taylor, L ^a   Emery, P ^b  

^a CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anti tumour necrosis factor; Biologics; DAS28; Disease modifying anti rheumatic drugs; European League Against Rheumatism response; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ALLERGY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EUROPEAN LEAGUE AGAINST RHEUMATISM; FEMALE; HEART INFARCTION; HUMAN; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT COURSE THERAPY; TWENTY EIGHT JOINT DISEASE ACTIVITY SCORE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849089648     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken103     Document Type: Article

References (15)

1. van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug insight resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26-34.
2. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iIi-iv, xi-xiii, 1-229.
4. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
5. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
6. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 2007; 46:626-30.
7. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
9. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
10. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
11. Jois RN, Masding A, Somerville M, Gaffney K, Scott DG. Rituximab therapy in patients with resistant rheumatoid arthritis: Real-life experience. Rheumatology 2007;46:980-2.
12. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: Biological and clinical implications. Lupus 2005;14:931-7.
13. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005;1051:559-69.
14. Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: Implications for rheumatoid arthritis. Arthritis Res Ther 2003;5(Suppl. 4):S12-6.
15. Corona R, Bigby M. What are the risks of serious infections and malignancies for patients treated with anti-tumor necrosis factor antibodies? Arch Dermatol 2007;143:405-6.